Granulomatosis With Polyangiitis, Hemophagocytic Syndrome
Conditions
Brief summary
The trial was designed as a single-center, randomized, double-blind, single-dose parallel controlled phase I study to evaluate the similarity of pharmacokinetics and safety of Meperizumab injection and NUCALA® in healthy male volunteers. The plan is to enroll 88 healthy subjects. After signing the written informed consent voluntarily, the subjects will undergo a series of examinations and information collection to determine whether they meet the inclusion criteria. The qualified subjects will be randomized and administered. Biological samples were collected and safety checked before and after administration according to protocol requirements. Adverse events occurred during the trial were collected, and the combination of drug use and non-drug treatment were asked and recorded in detail. When the 90% confidence interval of geometric mean ratio of the main pharmacokinetic parameters of Meperizumab injection and NUCALA® was within the range of 80.00%-125.00%, it was proved that the pharmacokinetic characteristics of the two were similar.
Interventions
DRUGMeperizumab injection
Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
DRUGNUCALA®
NUCALA® is a humanized monoclonal antibody of IgG1 injection
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* 1 Before the study, the informed consent was signed and the content, process and possible adverse reactions of the test were fully understood; * 2 Able to complete the research according to the requirements of the test protocol; * 3 Male subjects aged 18-55 (18 and 55 included); * 4 Body weight ≥ 50 kg ≤90 kg, body mass index (BMI) ≥ 19 ≤ 26kg/m2; * 5 Health status: No mental disorders, no history of cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system and metabolic abnormalities; * 6 Subjects had no pregnancy plans and voluntarily used effective contraception for at least 6 months from 2 weeks prior to self-medication to their last use of study medication.
Exclusion criteria
* 1 Previous neuropsychiatric, respiratory, cardiovascular, digestive, hemolymph, hepatic and renal dysfunction, endocrine, skeletal and musculoskeletal disorders, or other diseases that the investigator judged might affect drug metabolism or safety; * 2 Known allergy to meperizumab or its excipients; * 3 Known history of allergic disease or allergy or history of asthma disease; * 4 Prior treatment with meperizumab or an IL-5 receptor inhibitor, or other antibody or protein drugs that target the IL-5 receptor; * 5 Who received any live viral vaccines within 2 months prior to infusion of the study drug, or who needed to be vaccinated between the screening period and the end of the study, who used the study drug within 12 months prior to administration of the study drug or planned to receive any monoclonal antibodies or biologic drugs within 12 months after administration of the study drug; * 6 Patients who have unhealed wounds, ulcers or fractures, or who underwent major surgery within 3 months prior to infusion of the study drug, or who are expected to undergo major surgery within 2 months after study completion; * 7 Any prescription, over-the-counter, vitamin product or herbal medicine used in the 2 weeks prior to taking the study drug; * 8 Abnormal and clinically significant examinations during screening period; * 9 Blood donation or significant blood loss within 3 months prior to taking the study drug (& GT; 450 ml); * 10 Participated in any drug clinical trials within 3 months prior to taking the study drug; * 11 Those who smoked more than 5 cigarettes a day 3 months before the experiment; * 12 History of alcohol abuse (14 units of alcohol per week: 1 unit =360mL beer or 45mL 40% spirits or 150mL wine); * 13 Those who are screened positive for drugs or have a history of drug abuse in the past five years or have used drugs in the three months prior to the test; * 14 Screening positive for hepatitis (including hepatitis B and C), acquired immunodeficiency syndrome(AIDS) and syphilis; * 15 The subject is unable to complete the test due to personal reasons; * 16 Conditions that other researchers consider inappropriate for inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak concentration(Cmax) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Peak maximum plasma drug concentration |
| Area under drug concentration - time curve(AUC0-t) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Area under the curve from zero to the lowest detectable blood drug concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| half-life(T1/2) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | The time it takes for serum drug concentrations to drop by half |
| Elimination rate constant(λz) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | The slope of the terminal segment of a semi-logarithmic curve |
| Residual area percentage(AUC%Extrap) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | The percentage of the difference between AUC0-∞ and AUC0-t as a percentage of AUC0-t |
| Apparent clearance(CL/F) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Percentage of the body that eliminates organ-scavenging drugs |
| Apparent volume of distribution(Vd/F) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Apparent volume of distribution after non-intravenous administration |
| Physical examination | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | The doctor will percuss, look, and question the subject, and record any abnormalities in the skin, spine, or limbs |
| The area under the curve extrapolating from zero to infinity(AUC0-∞) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Area under the curve from zero to infinity |
| Pulse | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Abnormal pulse |
| Blood pressure | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Abnormal blood pressure |
| Electrocardiogram(ECG) QT Interval | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Abnormal ECG QT Interval |
| Anti-drug antibody(ADA) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | ADA positive |
| Neutralizing antibody(NAb) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | NAb positive |
| Body temperature | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Abnormal body temperature |
| Peak concentration time(Tmax) | 0 hours before administration (within 60 minutes before administration) to 2016 hours after administration | Time to reach maximum plasma concentration after dosing |
Countries
China
Contacts
Primary ContactHaimiao Yang, Master
Outcome results
None listed